Jane Meisel News Today

(CT News) - Breast cancer affects roughly one in eight women in the U.S. It is the second most common cancer for women in the country.........

If you notice this, call your doctor.

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Its no secret that cancer is a word that strikes fear into the minds of many. The thought of undergoing screening tests for this life-altering disease can be daunting, leading

Emory faculty and staff are frequently recognized for their work locally, nationally and internationally. Read a sampling of recent accolades, including awards for professional contributions and leadership appointments.

Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.

During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.

  A company whose goal is to identify those at risk for cancer has developed a way to screen for more than 60 cancer susceptibility genes. The work is being done at Emory Medicine’s department of human genetics. GPB’s Ellen Eldridge has more. Caption Young, Black women are disproportionally affected by breast cancer, which is associated with the BRCA genes. Credit: Photo by Godisable Jacob from Pexels A national public health initiative based out of Emory University School of...